Molecular, pharmacological and functional diversity of 5-HT receptors

Serotonin (5-hydroxytryptamine, 5-HT) is probably unique among the monoamines in that its effects are subserved by as many as 13 distinct heptahelical, G-protein-coupled receptors (GPCRs) and one (presumably a family of) ligand-gated ion channel(s). These receptors are divided into seven distinct classes (5-HT(1) to 5-HT(7)) largely on the basis of their structural and operational characteristics. Whilst this degree of physical diversity clearly underscores the physiological importance of serotonin, evidence for an even greater degree of operational diversity continues to emerge. The challenge for modern 5-HT research has therefore been to define more precisely the properties of the systems that make this incredible diversity possible. Much progress in this regard has been made during the last decade with the realisation that serotonin is possibly the least conservative monoamine transmitter and the cloning of its many receptors. Coupled with the actions of an extremely avid and efficient reuptake system, this array of receptor subtypes provides almost limitless signalling capabilities to the extent that one might even question the need for other transmitter systems. However, the complexity of the system appears endless, since posttranslational modifications, such as alternate splicing and RNA editing, increase the number of proteins, oligomerisation and heteromerisation increase the number of complexes, and multiple G-protein suggest receptor trafficking, allowing phenotypic switching and crosstalk within and possibly between receptor families. Whether all these possibilities are used in vivo under physiological or pathological conditions remains to be firmly established, but in essence, such variety will keep the 5-HT community busy for quite some time. Those who may have predicted that molecular biology would largely simplify the life of pharmacologists have missed the point for 5-HT research in particular and, most probably, for many other transmitters. This chapter is an attempt to summarise very briefly 5-HT receptor diversity. The reward for unravelling this complex array of serotonin receptor--effector systems may be substantial, the ultimate prize being the development of important new drugs in a range of disease areas.

[1]  J. Sutcliffe,et al.  The 5‐HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: A mechanism for neuronal suppression of reactive astrocytes , 1996, Glia.

[2]  M. Millan,et al.  Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO60-0175: a pharmacological analysis , 1999, Neuropharmacology.

[3]  R. Eglen,et al.  RS-102221: A Novel High Affinity and Selective, 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.

[4]  J. Fozard,et al.  The 5-HT4 receptor: a place in the sun. , 1992, Trends in pharmacological sciences.

[5]  S. Ross,et al.  Different effects on the responses of functional pre- and postsynaptic 5-HT1A receptors by repeated treatment of rats with the 5-HT1A receptor agonist 8-OH-DPAT , 1990, Neuropharmacology.

[6]  D. Middlemiss,et al.  L‐694,247: a potent 5‐HT1D receptor agonist , 1993, British journal of pharmacology.

[7]  R Hen,et al.  Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. , 2001, European journal of pharmacology.

[8]  John A. Peters,et al.  The 5-HT3B subunit is a major determinant of serotonin-receptor function , 1999, Nature.

[9]  C. Marsden,et al.  Pindolol‐insensitive [3H]‐5‐hydroxytryptamine binding in the rat hypothalamus; identity with 5‐hydroxytryptamine7 receptors , 1999, British journal of pharmacology.

[10]  K. Buchheit,et al.  The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. , 1995, Journal of medicinal chemistry.

[11]  G. H. Dreteler,et al.  Systemic and Regional Hemodynamic Effects of the 5‐Hydroxytryptamine1A Receptor Agonists Flesinoxan and 8‐Hydroxy-2(Di-N-Propylamino)Tetralin in the Conscious Rat , 1991, Journal of Cardiovascular Pharmacology.

[12]  A. Sleight,et al.  Characterization of Ro 04‐6790 and Ro 63‐0563: potent and selective antagonists at human and rat 5‐HT6 receptors , 1998, British journal of pharmacology.

[13]  D. Middlemiss,et al.  Importance of h5-HT1B Receptor Selectivity for 5-HT Terminal Autoreceptor Activity: an In Vivo Microdialysis Study in the Freely-moving Guinea-pig , 1997, Neuropharmacology.

[14]  T. Branchek,et al.  5-ht6 receptors as emerging targets for drug discovery. , 2000, Annual review of pharmacology and toxicology.

[15]  M. Jurzak,et al.  Human 5-hydroxytryptamine(5A) receptors activate coexpressed G(i) and G(o) proteins in Spodoptera frugiperda 9 cells. , 2000, Molecular pharmacology.

[16]  D. Boger,et al.  Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Mattei,et al.  Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. , 1993, Molecular pharmacology.

[18]  M. Erlander,et al.  A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.

[19]  M. Camilleri Review article: tegaserod. , 2001, Alimentary pharmacology & therapeutics.

[20]  A. Brown,et al.  5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. , 1999, Journal of medicinal chemistry.

[21]  M. Millan,et al.  5-HT1A receptors and the tail-flick response. IV. Spinally localized 5-HT1A receptors postsynaptic to serotoninergic neurones mediate spontaneous tail-flicks in the rat. , 1993, The Journal of pharmacology and experimental therapeutics.

[22]  R M Eglen,et al.  RS‐127445: a selective, high affinity, orally bioavailable 5‐HT2B receptor antagonist , 1999, British journal of pharmacology.

[23]  E. Kirkness,et al.  Evidence for Expression of Heteromeric Serotonin 5‐HT3 Receptors in Rodents , 2000, Journal of neurochemistry.

[24]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[25]  H. Saito,et al.  Inhibition by 5‐HT7 receptor stimulation of GABAA receptor‐activated current in cultured rat suprachiasmatic neurones. , 1994, The Journal of physiology.

[26]  A. Sleight,et al.  5-HT(6) receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. , 2001, European journal of medicinal chemistry.

[27]  M. J. Burton,et al.  SB-216641 and BRL-15572 – compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[28]  C. Langmead,et al.  The effect of SB‐269970, a 5‐HT7 receptor antagonist, on 5‐HT release from serotonergic terminals and cell bodies , 2001, British journal of pharmacology.

[29]  Allan Fletcher,et al.  Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist , 1995, Behavioural Brain Research.

[30]  M. Millan,et al.  Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists. , 1993, The Journal of pharmacology and experimental therapeutics.

[31]  T. Branchek,et al.  A subfamily of 5-HT1D receptor genes. , 1992, Trends in pharmacological sciences.

[32]  F. Monsma,et al.  Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. , 1995, The Journal of pharmacology and experimental therapeutics.

[33]  R. Eglen,et al.  Peripheral 5‐HT4 receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  R. Hen,et al.  5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors. , 1996, Molecular pharmacology.

[35]  L. D. van de Kar,et al.  Selective serotonin reuptake inhibitors and neuroendocrine function. , 1999, Life sciences.

[36]  M. Caron,et al.  The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1A receptor , 1988, Nature.

[37]  R. Myers,et al.  Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. , 1991, Science.

[38]  R. Beroukhim,et al.  Ultrastructure of the 5‐Hydroxytryptamine3 Receptor , 1995, Journal of neurochemistry.

[39]  D. Middlemiss,et al.  SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity , 1998, British journal of pharmacology.

[40]  D. Hoyer,et al.  Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyanopindolol. , 1985, European journal of pharmacology.

[41]  I. Forbes,et al.  In vivo properties of SB 200646A, a 5‐HT2C/2B receptor antagonist , 1994, British journal of pharmacology.

[42]  H. Kalkman RU 24969-induced locomotion in rats is mediated by 5-HT1A receptors , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[43]  T. Branchek,et al.  Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. , 1997, Life sciences.

[44]  J. Hagan,et al.  The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. , 1998, Journal of medicinal chemistry.

[45]  S. Lightowler,et al.  Activation of 5-HT2B Receptors in the Medial Amygdala causes Anxiolysis in the Social Interaction Test in the Rat , 1997, Neuropharmacology.

[46]  F. Lezoualc’h,et al.  Pharmacological characterization of the human 5‐HT4(d) receptor splice variant stably expressed in Chinese hamster ovary cells , 2000, British journal of pharmacology.

[47]  F. Lezoualc’h,et al.  Isolation of the serotoninergic 5‐HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6‐glial and CHO cell lines , 2000, British journal of pharmacology.

[48]  J. Palacios,et al.  Localization of 5-HT1B, 5-HT1Dα, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain , 1994, Neuropharmacology.

[49]  M. Chesselet,et al.  Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons , 2001, Pharmacology Biochemistry and Behavior.

[50]  Á. Pazos,et al.  Identification and Characterization of a New Serotonergic Recognition Site with High Affinity for 5‐Carboxamidotryptamine in Mammalian Brain , 1997, Journal of neurochemistry.

[51]  A. Kjaer,et al.  Adrenocorticotropic Hormone Secretion in Rats Induced by Stimulation with Serotonergic Compounds , 1999 .

[52]  C. Dourish,et al.  5‐HT2C receptor modulation and the treatment of obesity , 1999, Diabetes, obesity & metabolism.

[53]  M. Moskowitz,et al.  Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis , 1999, Neuropharmacology.

[54]  C. Sibella-Argüelles The proliferation of human T lymphoblastic cells induced by 5-HT1B receptors activation is regulated by 5-HT-moduline. , 2001, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[55]  D. Nelson,et al.  Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. , 1992, Molecular pharmacology.

[56]  M. Hamon Central and peripheral 5-HT3 receptors , 1992 .

[57]  D. Storm,et al.  Stimulation of Type 1 and Type 8 Ca2+/Calmodulin-sensitive Adenylyl Cyclases by the Gs-coupled 5-Hydroxytryptamine Subtype 5-HT7AReceptor* , 1998, The Journal of Biological Chemistry.

[58]  P P Humphrey,et al.  5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle. , 1983, European journal of pharmacology.

[59]  D. Middlemiss,et al.  SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. , 1999, European journal of pharmacology.

[60]  C. de Montigny,et al.  Autoregulatory properties of dorsal raphe 5‐HT neurons: Possible role of electrotonic coupling and 5‐HT1D receptors in the rat brain , 1996, Synapse.

[61]  D. Reiss,et al.  Characterization of 5-hydroxytryptamine receptors in rat stomach fundus. , 1985, The Journal of pharmacology and experimental therapeutics.

[62]  G. Fillion,et al.  Autoradiographic characterization of [3H]-5-HT-moduline binding sites in rodent brain and their relationship to 5-HT1B receptors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Fozard,et al.  The 5-HT4 receptor: naughty, but nice. , 1989, Trends in pharmacological sciences.

[64]  M. Millan,et al.  Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study , 1998 .

[65]  T. Blackburn,et al.  BW 723C86, a 5-HT2B Receptor Agonist, Causes Hyperphagia and Reduced Grooming in Rats , 1997, Neuropharmacology.

[66]  E. A. Forster,et al.  Direct evidence for an important species difference in the mechanism of 8‐OH‐DPAT‐induced hypothermia , 1991, British journal of pharmacology.

[67]  D. Sibley,et al.  Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor , 1996, Journal of neurochemistry.

[68]  J. Palacios,et al.  Homogeneous 5-HT1D recognition sites in the human substantia nigra identified with a new iodinated radioligand. , 1991, European journal of pharmacology.

[69]  M. Millan,et al.  Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo , 1998, Neuropharmacology.

[70]  D. Hoyer Molecular pharmacology and biology of 5-HT1C receptors. , 1988, Trends in pharmacological sciences.

[71]  U. Knigge,et al.  Differential Effect of Serotonin 5-HT1A Receptor Antagonists on the Secretion of Corticotropin and Prolactin , 2001, Neuroendocrinology.

[72]  G. Reynolds,et al.  Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders , 1995, Behavioural Brain Research.

[73]  C. Marsden,et al.  Involvement of 5‐HT2 receptors in the behaviours produced by intrathecal administration of selected 5‐HT agonists and the TRH analogue (CG 3509) to rats , 1989, British journal of pharmacology.

[74]  E. Schröck,et al.  Assignment of a human homolog of the mouse Htr3 receptor gene to chromosome 11q23.1-q23.2. , 1995, Genomics.

[75]  J. Bockaert,et al.  Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. , 1999, Molecular pharmacology.

[76]  D. Hoyer,et al.  A proposed new nomenclature for 5-HT receptors. , 1993, Trends in pharmacological sciences.

[77]  D. Middlemiss,et al.  The 5‐HT1B Receptors , 1990, Annals of the New York Academy of Sciences.

[78]  I. Boyd,et al.  Urinary disorders associated with cisapride , 1994 .

[79]  A. Sleight,et al.  Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. , 1995, Molecular pharmacology.

[80]  B. O'dowd,et al.  Oligomerization of Dopamine and Serotonin Receptors , 2000, Neuropsychopharmacology.

[81]  H. Kao,et al.  The 5‐HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. , 1995, The EMBO journal.

[82]  K. Fink,et al.  Evidence for presynaptic location of inhibitory 5-HT1D\-like autoreceptors in the guinea-pig brain cortex , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[83]  P. Celada,et al.  How does pindolol improve antidepressant action? , 2001, Trends in pharmacological sciences.

[84]  M. Millan,et al.  Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors. , 1997, European journal of pharmacology.

[85]  R Hen,et al.  Enhanced aggressive behavior in mice lacking 5-HT1B receptor. , 1994, Science.

[86]  Lynn P. Martin,et al.  Electrophysiological comparison of 5-Hydroxytryptamine1A receptor antagonists on dorsal raphe cell firing. , 1999, The Journal of pharmacology and experimental therapeutics.

[87]  R. Hen,et al.  Elevated alcohol consumption in null mutant mice lacking 5–HT1B serotonin receptors , 1996, Nature Genetics.

[88]  R. Clark,et al.  Medicinal Chemistry of 5-HT4 Receptor Ligands , 1998 .

[89]  T. Branchek,et al.  Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation. , 1998, The Journal of pharmacology and experimental therapeutics.

[90]  G. Reynolds,et al.  5‐Hydroxytryptamine (5‐HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases , 1995, British journal of pharmacology.

[91]  T. Branchek,et al.  A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5‐ht7 receptor in rat brain , 1996, British journal of pharmacology.

[92]  R. Eglen,et al.  Characterization and distribution of putative 5‐ht7 receptors in guinea‐pig brain , 1995, British journal of pharmacology.

[93]  M. Jurzak,et al.  Cloning and Expression of a Human Serotonin 5‐HT4 Receptor cDNA , 1997, Journal of neurochemistry.

[94]  M. Teitler,et al.  Quantitative autoradiography of 5-CT-sensitive (5-HT1D) and 5-CT-insensitive (5-HT1E) serotonin receptors in human brain , 1992, Neuroscience Letters.

[95]  G. Martin,et al.  Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. , 1996, Trends in pharmacological sciences.

[96]  J. Hagan,et al.  Characterization of SB‐269970‐A, a selective 5‐HT7 receptor antagonist , 2000, British journal of pharmacology.

[97]  D. Middlemiss,et al.  Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue , 2000 .

[98]  C. Glass,et al.  The Pharmacological and Functional Characteristics of the Serotonin 5-HT3A Receptor Are Specifically Modified by a 5-HT3B Receptor Subunit* , 1999, The Journal of Biological Chemistry.

[99]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[100]  G. P. Lewis The inhibition by morphine of the action of smooth muscle stimulants on the guinea-pig intestine. , 1960, British journal of pharmacology and chemotherapy.

[101]  M. Jurzak,et al.  Structure of the Human Serotonin 5‐HT4 Receptor Gene and Cloning of a Novel 5‐HT4 Splice Variant , 2000, Journal of neurochemistry.

[102]  I. Martin,et al.  Molecular biology of 5-HT receptors , 1994, Neuropharmacology.

[103]  H. Lübbert,et al.  Expression of serotonin receptor mRNAs in blood vessels , 1995, FEBS letters.

[104]  G. Tunnicliff Molecular basis of buspirone's anxiolytic action. , 1991, Pharmacology & toxicology.

[105]  G. W. Price,et al.  Interaction of serotonin autoreceptor antagonists in the rat dorsal raphe nucleus: an in vitro fast cyclic voltammetry study , 2001, Neuroscience Letters.

[106]  R. Nicholson,et al.  Anesthetic-like Interaction of the Sleep-inducing Lipid Oleamide with Voltage-gated Sodium Channels in Mammalian Brain , 2001, Anesthesiology.

[107]  P. Hartig,et al.  Messenger RNA Editing of the Human Serotonin 5-HT2C Receptor , 1999, Neuropsychopharmacology.

[108]  J. D. den Boer,et al.  Serotonergic drugs in the treatment of depressive and anxiety disorders , 2000, Human psychopharmacology.

[109]  R. Emeson,et al.  Regulation of serotonin-2C receptor G-protein coupling by RNA editing , 1997, Nature.

[110]  M. Jurzak,et al.  The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells. , 1998, European journal of pharmacology.

[111]  G. Martin,et al.  Receptors for 5-Hydroxytryptamine: Current perspectives on classification and nomenclature , 1994, Neuropharmacology.

[112]  A. Eison,et al.  Effects of Antidepressants on 5-HT7 Receptor Regulation in the Rat Hypothalamus , 1999, Neuropsychopharmacology.

[113]  S. Bromidge,et al.  Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134). , 2001, Bioorganic & medicinal chemistry letters.

[114]  D. Cox,et al.  5-HT2B receptor signaling in the rat stomach fundus: dependence on calcium influx, calcium release and protein kinase C , 1995, Behavioural Brain Research.

[115]  C. Niswender,et al.  Serotonin 5‐HT2C Receptor RNA Editing Alters Receptor Basal Activity , 1999, Journal of neurochemistry.

[116]  D. Sibley,et al.  Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. , 1993, The Journal of biological chemistry.

[117]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[118]  P J Lovell,et al.  A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970). , 2000, Journal of medicinal chemistry.

[119]  I. Lucki,et al.  Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. , 2001, The Journal of pharmacology and experimental therapeutics.

[120]  J. Hagan,et al.  The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[121]  J. Hagan,et al.  Functional characterisation of the human cloned 5‐HT7 receptor (long form); antagonist profile of SB‐258719 , 1998, British journal of pharmacology.

[122]  R. Fischmeister,et al.  Molecular and functional characterization of a 5‐HT4 receptor cloned from human atrium , 1997, FEBS letters.

[123]  H. Vijverberg,et al.  5-HT3 receptors and neurotransmitter release in the CNS: a nerve ending story? , 2000, Trends in Neurosciences.

[124]  T. Branchek,et al.  Molecular biology and potential functional role of 5-HT5, 5-HT6, and 5-HT7 receptors , 2000 .

[125]  M. Kanje,et al.  5-HT1B and 5-HT1D receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase , 2001, Brain Research.

[126]  S H Snyder,et al.  Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. , 1979, Molecular pharmacology.

[127]  D. S. Cowen,et al.  5-HT7 receptors activate the mitogen activated protein kinase extracellular signal related kinase in cultured rat hippocampal neurons , 2001, Neuroscience.

[128]  D. Hoyer,et al.  Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. , 1985, European journal of pharmacology.

[129]  G. Martin,et al.  5-HT Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome , 1997, Neuropharmacology.

[130]  B. Largent,et al.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.

[131]  M. Tricklebank The behavioural response to 5-HT receptor agonists and subtypes of the central 5-HT receptor , 1985 .

[132]  D. Middlemiss,et al.  Pharmacological characterisation of human 5-HT2 receptor subtypes. , 2001, European journal of pharmacology.

[133]  B. O'dowd,et al.  Serotonin 5‐HT1B and 5‐HT1D receptors form homodimers when expressed alone and heterodimers when co‐expressed , 1999, FEBS letters.

[134]  R M Eglen,et al.  Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. , 1999, Circulation.

[135]  I. Forbes,et al.  In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties , 1996, British journal of pharmacology.

[136]  I. Lucki 5-HT1 receptors and behavior , 1992, Neuroscience & Biobehavioral Reviews.

[137]  M. Hamon,et al.  Developmental Changes in the Differential Expression of Two Serotonin 5‐HT3 Receptor Splice Variants in the Rat , 1995, Journal of neurochemistry.

[138]  T. Blackburn,et al.  Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system , 1997, Neuroscience.

[139]  T. Shinkai,et al.  Novel polymorphism in the 5′-upstream region of the human 5-HT6 receptor gene and schizophrenia , 2001, Neuroscience Letters.

[140]  M. Piercey,et al.  Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist. , 1994, The Journal of pharmacology and experimental therapeutics.

[141]  J. Schwartz,et al.  Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[142]  G. Fillion,et al.  Immunocytochemical localization of neurons expressing 5-HT-moduline in the mouse brain , 1997, Neuropharmacology.

[143]  D. Middlemiss,et al.  Characterization of SB‐271046: A potent, selective and orally active 5‐HT6 receptor antagonist , 2000, British journal of pharmacology.

[144]  P. Barone,et al.  Quantitative autoradiography of 5-HT1E binding sites in rodent brains: effect of lesion of serotonergic neurones. , 1993, European journal of pharmacology.

[145]  P. Barone,et al.  Quantitative autoradiography of 5-HT1D and 5-HT1E binding sites labelled by [3H]5-HT, in frontal cortex and the hippocampal region of the human brain , 1994, Brain Research.

[146]  J. Crabbe,et al.  Genetics of mouse behavior: interactions with laboratory environment. , 1999, Science.

[147]  Colleen M Niswender,et al.  RNA Editing of the Human Serotonin 5-HT2C Receptor: Alterations in Suicide and Implications for Serotonergic Pharmacotherapy , 2001, Neuropsychopharmacology.

[148]  S. Snyder,et al.  Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. , 1976, Molecular pharmacology.

[149]  N. Barnes,et al.  Neurochemical Consequences Following Pharmacological Manipulation of Central 5-HT4 Receptors , 1998 .

[150]  J. Hagan,et al.  [3H]‐SB‐269970 – A selective antagonist radioligand for 5‐HT7 receptors , 2000 .

[151]  B. Roth,et al.  2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. , 2000, Journal of medicinal chemistry.

[152]  T. Gray,et al.  5-HT2A Receptors Stimulate ACTH, Corticosterone, Oxytocin, Renin, and Prolactin Release and Activate Hypothalamic CRF and Oxytocin-Expressing Cells , 2001, The Journal of Neuroscience.

[153]  R. Fischmeister,et al.  Cloning, Expression, and Pharmacology of Four Human 5‐Hydroxytryptamine4 Receptor Isoforms Produced by Alternative Splicing in the Carboxyl Terminus , 1998, Journal of neurochemistry.

[154]  A. Sleight,et al.  A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze , 2001, Neuropharmacology.

[155]  P B Hedlund,et al.  Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. , 1999, Biochemical pharmacology.

[156]  M. Bourin,et al.  5-HT-moduline, a 5-HT(1B/1D) receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis. , 1998, European journal of pharmacology.

[157]  D. Middlemiss,et al.  Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. , 1989, Trends in pharmacological sciences.

[158]  B. O'dowd,et al.  Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. , 2000, The Journal of biological chemistry.

[159]  J. Vane,et al.  An analysis of the direct and indirect actions of drugs on the isolated guinea-pig ileum. , 1963, British journal of pharmacology and chemotherapy.

[160]  J. Sutcliffe,et al.  Oleamide‐induced Modulation of 5‐Hydroxytryptamine Receptor‐mediated Signaling a , 1998, Annals of the New York Academy of Sciences.

[161]  B. Sacks,et al.  Eltoprazine in aggressive mentally handicapped patients: a double‐blind, placebo- and baseline‐controlled multi‐centre study , 1994, International clinical psychopharmacology.

[162]  M. Cohen,et al.  Contractile serotonergic receptor in rat stomach fundus. , 1987, The Journal of pharmacology and experimental therapeutics.

[163]  I A Cliffe,et al.  A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. , 1995, European journal of pharmacology.

[164]  T. Branchek,et al.  Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. , 1993, The Journal of biological chemistry.

[165]  R. Kohen,et al.  Four 5‐Hydroxytryptamine7 (5‐HT7) Receptor Isoforms in Human and Rat Produced by Alternative Splicing: Species Differences Due to Altered Intron‐Exon Organization , 1997, Journal of neurochemistry.

[166]  A. Meneses Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation , 2001, Behavioural Brain Research.

[167]  J. Seckl,et al.  Acute restraint stress increases 5-HT7 receptor mRNA expression in the rat hippocampus , 2001, Neuroscience Letters.

[168]  A. Sleight,et al.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. , 1998, The Journal of pharmacology and experimental therapeutics.

[169]  R. Eglen,et al.  Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea-pig isolated ileum. , 1995, European journal of pharmacology.

[170]  M. Hamon,et al.  [Role of serotonin and other neuroactive molecules in the physiopathogenesis of migraine. Current hypotheses]. , 2000, Pathologie-biologie.

[171]  J. C. Winter,et al.  The interactions of typical and atypical antipsychotics with the (−)2,5,-dimethoxy-4-methamphetamine (DOM) discriminative stimulus , 1995, Neuropharmacology.

[172]  G. Aghajanian,et al.  Serotonin and Hallucinogens , 1999, Neuropsychopharmacology.

[173]  H. Boddeke,et al.  5‐HT2B receptor‐mediated calcium release from ryanodine‐sensitive intracellular stores in human pulmonary artery endothelial cells , 1996, British journal of pharmacology.

[174]  D. Middlemiss,et al.  Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[175]  G. Fillion,et al.  5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety , 1999, Neuroscience.

[176]  S. Cheetham,et al.  Evidence that RU 24969‐induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5‐HT1B receptor , 1993, British journal of pharmacology.

[177]  P. Szot,et al.  Function and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing , 1998, Neuropharmacology.

[178]  R. Eglen,et al.  Cloning, expression and pharmacology of a truncated splice variant of the human 5‐HT7 receptor (h5‐HT7(b)) , 1997 .

[179]  S. Watts,et al.  Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. , 2001, The Journal of pharmacology and experimental therapeutics.

[180]  M. Erlander,et al.  Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[181]  L H Parsons,et al.  Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[182]  J. Leysen,et al.  Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. , 1996, Molecular pharmacology.

[183]  R Hen,et al.  Regional changes in density of serotonin transporter in the brain of 5‐HT1A and 5‐HT1B knockout mice, and of serotonin innervation in the 5‐HT1B knockout , 2001, Journal of neurochemistry.

[184]  J. A. Peters,et al.  Cloning and functional expression of an apparent splice variant of the murine 5-HT3 receptor A subunit. , 1993, European journal of pharmacology.

[185]  L. Sanders,et al.  5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptors in human atrium: facilitation by chronic β-adrenoceptor blockade , 1994, Naunyn-Schmiedeberg’s Archives of Pharmacology.

[186]  W. Feniuk,et al.  5-Carboxamidotryptamine: a potent agonist mediating relaxation and elevation of cyclic AMP in the isolated neonatal porcine vena cava. , 1986, Life sciences.

[187]  M Toth,et al.  Increased anxiety of mice lacking the serotonin1A receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[188]  R. Schreiber,et al.  (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. , 1995, The Journal of pharmacology and experimental therapeutics.

[189]  C. Davies,et al.  SB‐272183, a selective 5‐HT1A, 5‐HT1B and 5‐HT1D receptor antagonist in native tissue , 2001, British journal of pharmacology.

[190]  J. Palacios,et al.  Characterization of human serotonin 1D and 1B receptors using [ 3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[191]  N. Barnes,et al.  Allosteric modulation of 5-HT3 receptors: focus on alcohols and anaesthetic agents. , 1996, Trends in pharmacological sciences.

[192]  F. O. Risinger,et al.  Oral operant ethanol self-administration in 5-HT1b knockout mice , 1999, Behavioural Brain Research.

[193]  J. Sutcliffe,et al.  The Endogenous Lipid Oleamide Activates Serotonin 5‐HT7 Neurons in Mouse Thalamus and Hypothalamus , 1999, Journal of neurochemistry.

[194]  P. Bradley,et al.  Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine , 1986, Neuropharmacology.

[195]  M. Cohen,et al.  Further evidence that the serotonin receptor in the rat stomach fundus is not 5HT1A or 5HT1B. , 1986, Life sciences.

[196]  R. Eglen 5-Hydroxytryptamine (5-HT)4 receptors and central nervous system function: an update. , 1997, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[197]  P. Pauwels 5-HT 1B/D receptor antagonists. , 1997, General pharmacology.

[198]  E. Zifa,et al.  A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT 1B 1D receptors , 1995, Behavioural Brain Research.

[199]  D. Sibley,et al.  Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[200]  M. Neal,et al.  Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[201]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[202]  J. Bockaert,et al.  5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. , 1994, Neuroreport.

[203]  G. Fillion,et al.  Acute stress induces a differential increase of 5-HT-moduline (LSAL) tissue content in various rat brain areas , 1999, Brain Research.

[204]  Colleen M. Niswender,et al.  RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity* , 1999, The Journal of Biological Chemistry.

[205]  Kirk W. Johnson,et al.  5‐HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs , 1997, Neuroreport.

[206]  M. Millan,et al.  5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. , 1997, European journal of pharmacology.

[207]  A. Brown,et al.  SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.

[208]  G. Fillion,et al.  Mapping of 5-HT-moduline binding sites in guinea-pig brain by film and digital autoradiography , 1998, Brain Research.

[209]  C. Waeber,et al.  [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[210]  J. Stamford,et al.  Multiple 5-HT1 autoreceptor subtypes govern serotonin release in dorsal and median raphé nuclei , 2001, Neuropharmacology.

[211]  J. Bockaert,et al.  Cloning and expression of human 5‐HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase , 1997, Neuroreport.

[212]  T. Mansour,et al.  Serotonin receptor-mediated activation of adenylate cyclase in the neuroblastoma NCB.20: a novel 5-hydroxytryptamine receptor. , 1990, Molecular pharmacology.

[213]  D. Hoyer Serotonin 5-HT3, 5-HT4, and 5-HT-M receptors. , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[214]  G. Kennett,et al.  Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors , 2001, Neuropharmacology.

[215]  M. Buhot,et al.  5-HT1B receptor knock out — behavioral consequences , 1995, Behavioural Brain Research.

[216]  M. Gershon Review article: roles played by 5‐hydroxytryptamine in the physiology of the bowel , 1999, Alimentary pharmacology & therapeutics.

[217]  B. O'dowd,et al.  Orphan G protein-coupled receptors in the CNS. , 2001, Current opinion in pharmacology.

[218]  K. Simansky Serotonin and the Structure of Satiation , 1998 .